Patent details

Basic Information

Publication number:

EP2252300

PCT Application Number:

PCT/US/2009/034718

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP097119440

PCT Publication Number:

WO/2009/105675

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

USE OF 2,4-PYRIMIDINEDIAMINES FOR THE TREATMENT OF ATHEROSCLEROSIS

French Title of Invention:

UTILISATION DE 2,4-PYRIMIDINEDIAMINES POUR LE TRAITEMENT DE L'ATHÉROSCLÉROSE

German Title of Invention:

VERWENDUNG VON 2,4-PYRIMIDINDIAMINEN ZUR BEHANDLUNG VON ATHEROSKLEROSE

SPC Number:

Dates

Filing date:

20/02/2009

Grant date:

19/10/2016

EP Publication Date:

19/10/2016

PCT Publication Date:

27/08/2009

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

24/11/2010

EP B1 Publication Date:

19/10/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

20/02/2024

Expiration date:

20/02/2029

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

20/02/2009

 

 

Name:

Rigel Pharmaceuticals Inc.

Address:

1180 Veterans Boulevard, South San Francisco, CA 94080, United States (US)

Agent

Name:

ARONOVA S.A.

From:

05/01/2017

Address:

PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)

To:

Inventor

1

Name:

MASUDA Esteban

Address:

United States (US)

2

Name:

SCHMITZ Jochen

Address:

United States (US)

Priority

Priority Number:

30903

Priority Date:

22/02/2008

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 31/5383;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

27/02/2023

Last Annual Fee Paid Number:

15

Last Annual Fee Paid Amount:

213 Euro

Payer:

Computer Packages INC

Filing date	Document type	Number of pages
05/01/2017	Incoming Correspondence (Post)	1